Payment overview · 2025
General Payments
$79.31
3 reported records · 2 companies
Healthcare provider profile · identity verified
Sanjay K Vora, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MARION, OH · NPI 1801827977
Verified facts
What the public records show
CMS Open Payments records show Sanjay K Vora, M.D. received $79.31 in general payments during 2025 across 3 reported records.
Mallinckrodt Hospital Products Inc. accounted for 74.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $58.76 | 74.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.55 | 25.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.31 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $58.76 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 722 | 183 |
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 83 |
| Lisinopril | Lisinopril | 311 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 82 |
| Omeprazole | Omeprazole | 263 | 72 |
| Famotidine | Famotidine | 227 | 64 |
| Losartan Potassium | Losartan Potassium | 213 | 61 |
| Allopurinol | Allopurinol | 198 | 50 |
| Metformin Hcl Er | Metformin Hcl | 177 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 173 | 76 |
| Potassium Chloride | Potassium Chloride | 162 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 36 |
| Carvedilol | Carvedilol | 133 | 33 |
| Furosemide | Furosemide | 128 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 50 |
| Celecoxib | Celecoxib | 111 | 30 |
| Simvastatin | Simvastatin | 103 | 26 |
| Valsartan | Valsartan | 103 | 25 |
| Spironolactone | Spironolactone | 100 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 25 |
| Meloxicam | Meloxicam | 89 | 24 |
| Metformin Hcl | Metformin Hcl | 83 | 29 |
| Montelukast Sodium | Montelukast Sodium | 76 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 74 | 19 |
| Glimepiride | Glimepiride | 72 | 15 |
| Gabapentin | Gabapentin | 71 | 28 |
| Sertraline Hcl | Sertraline Hcl | 69 | 21 |
| Alendronate Sodium | Alendronate Sodium | 68 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 12 |
| Finasteride | Finasteride | 49 | 15 |
| Azithromycin | Azithromycin | 48 | 41 |
| Primidone | Primidone | 48 | 14 |
| Trazodone Hcl | Trazodone Hcl | 48 | 12 |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Irbesartan | Irbesartan | 47 | 13 |
| Sucralfate | Sucralfate | 46 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 35 | suppressed |
| Prednisone | Prednisone | 35 | 32 |
| Pregabalin | Pregabalin | 35 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 28 |
| Amoxicillin | Amoxicillin | 31 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 18 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Repaglinide | Repaglinide | 31 | 11 |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Eliquis | Apixaban | 30 | 13 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 14 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.31 · 3 records | Mallinckrodt Hospital Products Inc. | ACTHAR, Veozah | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error